New Research Compares Anxiety Diagnosis Approaches


A direct comparison between the 2 popular diagnostic approaches for anxiety did not find significant differences.

Marie-France Marin, PhD

Marie-France Marin, PhD

Both popular methods for diagnosing anxiety and other mental health disorders have value, according to a new study.

A team, led by Marie-France Marin, PhD, Department of Psychology, Université du Québec à Montréal, examined threat conditioning and extinction protocol to conduct DSM-IV-based and Research Domain Criteria-based assessments of psychophysiological, neural, and psychometric responses for patients with and without anxiety disorders.

The Research Domain Criteria is an initiative from the National Institute of Mental Health to guide neuropsychiatry toward precision medicine. The guide was initially created in response to the overlap of clinical manifestations between DSM-IV diagnoses within a category.

It is unknown whether DSM-IV-based and Research Domain Criteria-based analytic approaches provide distinct or similar information regarding the fear circuitry of patients with anxiety disorders.

One example of those issue is when anxiety disorders comprise a DSM-IV category that includes diagnoses that differ from each other but are all characterized by dysregulated fear levels.

Personalized medicine could be better served with the inclusion of both DSM-IV-based and research domain criteria-based approaches because they provide distinct and complementary information.

The cross-sectional study included 114 adults with and without anxiety disorders. The categorical DSM-IV-based approach indicated that patients with an anxiety disorder, irrespective of DSM-IV diagnosis, exhibited hypoactivation in the ventromedial prefrontal cortex during extinction recall.

The study was conducted at the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital between March 2013 and May 2015. The investigators performed functional magnetic resonance on adults 18-65 years old with specific phobia, generalized anxiety disorder, social anxiety disorder, and panic disorder. The sutyd also included a control group without anxiety disorders.

Of the 114 patients, 93 patients had at least 1 anxiety disorder, including specific phobia, generalized anxiety disorder, social anxiety disorder, or panic disorders, while 21 participants did not have an anxiety disorder.

The investigators measured skin conductance responses and blood oxygenated level-dependent responses during the threat and extinction protocol and performed the categorical analysis by grouping participants based on their primary DSM-IV diagnosis.

The dimensional analysis was performed by regrouping participants, irrespective of their diagnosis based on their skin conductance responses to shock delivery during threat conditioning.

The study revealed that categorical DSM-IV-based approaches show that all anxiety disorder groups exhibited hypoactivation in the ventromedial prefrontal cortex during extinction recall

On the other hand, the Research Domain Criteria-based approach revealed that higher arousal to the unconditioned stimulus is linked to higher threat responses during extinction recall (for skin conductance responses, P = .01 and in functional magnetic resonance imaging results, P = .02).

The direct comparison of the 2 methodologies did not yield significant findings, suggesting no overlap between the approaches.

“The data obtained from both approaches indicated complementary yet distinct findings,” the authors wrote. “The findings highlight the validity and importance of using both categorical and dimensional approaches to optimize understanding of the etiology and treatment of anxiety symptoms.”

The study, “Multimodal Categorical and Dimensional Approaches to Understanding Threat Conditioning and Its Extinction in Individuals With Anxiety Disorders,” was published online in JAMA Psychiatry.

Related Videos
Insight on the Promising 52-Week KarXT Data with Rishi Kakar, MD
Sunny Rai, PhD: “I” Language Markers Do Not Detect Depression in Black Individuals
Rebecca A. Andrews, MD: Issues and Steps to Improve MDD Performance Measures
A Voice Detecting Depression? Lindsey Venesky, PhD, Discusses New Data
Daniel Karlin, MD: FDA Grants Breakthrough Designation to MM120 for Anxiety
Leesha Ellis-Cox: Steps to Closing the Bipolar Disorder Diagnosis Gap for Blacks
Daniel Greer, PharmD: Reduction in Rehospitalizations with Antipsychotic Injections for Schizophrenia
© 2024 MJH Life Sciences

All rights reserved.